John P. Butler, Director at Zynerba Pharmaceuticals, Inc. (ZYNE), bought 5,000 shares at $6.43 ($32K) on 2018-08-22, disclosed to the SEC on 2018-08-22.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| AKBA | SELL | 2025-03-04 | $170K | — | Filing → |
| AKBA | SELL | 2025-02-04 | $606K | — | Filing → |
| AKBA | SELL | 2024-03-01 | $147K | — | Filing → |